ANEB Anebulo Pharmaceuticals
- 3.080
- +1.000+48.08%
- 2.800
- -0.280-9.09%
Anebulo Pharmaceuticals News
After-Market Stock Rise In Anebulo (ANEB) Indicates Potential Shift In Investor Sentiment
Express News | Anebulo Pharmaceuticals Awarded Nida Grant for Its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
Express News | Anebulo Receives $1.9M Grant From NIDA For Investigational IV Treatment Of Cannabis Toxic Effects
Express News | Lifecore Biomedical: 22Nw Will Withdraw Notice of Nominations of Director Candidates at 2023 Annual Meeting
Express News | Lifecore Biomedical Inc - 22Nw Signs Standstill and Support Agreement
Express News | Lifecore Biomedical Inc - to Add Four Directors to Board
Express News | Lifecore Biomedical Announces Cooperation Agreement With 22Nw
12 Health Care Stocks Moving In Friday's Intraday Session
Anebulo Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Anebulo Pharmaceuticals, Inc. Q3 Basic EPS USD -0.06
Express News | Anebulo Pharmaceuticals, Inc. Q3 Net Income USD -1.7 Million
Express News | Anebulo Pharmaceuticals, Inc. Q3 Operating Expenses USD 1.7 Million
Express News | Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What's the Latest?
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
Express News | Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
Express News | Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB
Analysis
Price Target
No Data
No Data
